Poison center counts are one of the few public measures of how often people get hurt by GLP-1 drugs and unapproved peptides outside a clinic.
The numbers have risen fast. The Washington Poison Center took 543 GLP-1 calls from January through September 2026, double the same months of 2025, and said medication errors such as tenfold overdoses were the most common reason. In Georgia, calls involving GLP-1 drugs went from 38 in 2021 to 655 by mid-November 2026, and the center's director said about 15% of callers need an emergency room visit.
Gray-market products account for a growing share. Georgia's center said about one in five GLP-1 calls over two years involved unapproved drugs, including retatrutide, which Eli Lilly is still testing and which is sold online as powder that buyers mix and measure themselves.
See #gray-market and #retatrutide.
About 15% of callers need emergency room evaluation, and about one in five GLP-1 calls over the past two years involved unapproved gray-market drugs, Georgia Poison Center director Gaylord Lopez told WSB-TV. People confuse milligrams with milliliters and use insulin syringes, he said. Hayley Lithwick described paying about $200 online for powdered retatrutide labeled "not for human use" after losing Zepbound coverage, then taking about twice the intended dose.
The Washington Poison Center took 543 calls involving GLP-1 drugs from January through September 2026, up from 272 in the same period of 2025, KIRO 7 reported. The center's Jimmy Leonard said medication errors are the most common reason, including tenfold overdoses such as taking 2.5 mg instead of 0.25 mg, and warned that retatrutide sold online as a research chemical may be contaminated. One woman who lost insurance coverage for Zepbound bought retatrutide online for about $200, mixed the powder herself, and likely doubled her dose, leaving her with heavy sweating, nausea, and a racing heart.
Medscape published 'Unapproved Retatrutide Use Challenges Clinicians' on Friday June 26, 2026, documenting the scale of gray-market and clinic-channel retatrutide use that runs parallel to Eli Lilly's Phase 3 TRIUMPH program. Two anchor data points: retatrutide exposures reported to US poison-control centers averaged 95 cases per month in Q1 2026, a 265% increase from the average across the last four months of 2025; and at least 50 US clinics staffed by licensed physicians and nurse practitioners openly advertise the unapproved drug to weight-loss patients. The piece frames the practical challenge for primary-care and obesity-medicine clinicians whose patients arrive already taking retatrutide sourced from research-chemical vendors, online clinics, or compounding pharmacies operating outside the FDA bulks-list framework. The Drug Topics companion story (same week) added that the prescribing rate is 'alarming' to obesity-medicine specialty groups. The data lands the same week as Senator Hassan's June 25 letter to HHS Secretary RFK Jr. demanding answers on the FDA-Lilly compassionate-use grant to a 79-year-old patient: one VIP-adjacent individual received the real drug through a sanctioned pathway while at least 50 clinics distribute the unregulated version at scale.